福元医药2025年度权益分派实施公告深度解读

一、公告核心要点

• 每股分配比例： A股每股现金红利0.5元（含税）。
• 差异化分红： 本次分配方案采用差异化分红，实际参与分配的总股本为4.68亿股（公司回购专用账户中1,200万股不参与分配）。
• 股权登记及发放日期： 股权登记日为2026年6月1日，除权（息）日及现金红利发放日均为2026年6月2日。
• 除权（息）参考价格： 由于差异化分红，每股现金红利折算后约为0.49元/股，因此除权（息）参考价格为“前收盘价-0.49元”。
• 仅现金分红： 本次分配方案不包括资本公积转增股本等其他形式，仅为现金红利。

二、对股东影响及潜在价格敏感信息

• 回购股份不参与分红： 公司回购专用账户中的1,200万股不参与分配，对应分红将全部由实际流通股东享有，有助于提升每位流通股东的分红收益。
• 税务处理：
  • 个人及基金持有者分红暂不扣税，需在转让股票时根据持股期限补税。持股不满1个月的，税负20%；持股1个月至1年（含1年）税负10%；持股超过1年免税。
  • QFII和沪港通投资者红利由公司代扣10%所得税，实际每股红利0.45元。
  • 内地机构及法人股东自行申报缴税，实际派发0.50元/股。
• 红利发放渠道：
  • 无限售流通股红利由中国结算上海分公司委托派发，指定交易账户可直接领取。
  • 主要股东（新和成控股集团有限公司、新昌勤进投资有限公司、北京华康泰丰科技有限责任公司、宣城人和投资合伙企业）现金红利由公司自行派发。
• 价格敏感信息：
  • 现金分红比例高，显示公司盈利能力和现金流状况稳健，可能对投资者情绪和股价形成正面推动。
  • 差异化分红机制下，实际派发红利比表面分红比例略低，投资者需关注除权价格及分红到账金额的实际影响。
  • 公司回购股份不参与分配，分红集中向流通股东倾斜，提升单股分红收益。

三、详细时间表及操作提示

红利领取方式：已办理指定交易的投资者将在发放日自动收到红利，未办理指定交易的需尽快办理。

四、投资者关注事项

• 本次现金分红方案体现出公司对股东回报的重视，有助于吸引长期价值投资者。
• 税务政策复杂，建议投资者关注自身持股期限及税务申报要求，合理规划投资行为。
• 如有疑问可联系董秘办：010-65020399。

五、结语

本次分红方案显示福元医药稳健的经营和良好的现金流，有望对公司股价产生积极影响。建议投资者结合自身实际情况，关注除权后的价格变动与税务影响。

免责声明：本文基于公开信息整理，不构成投资建议。投资有风险，入市须谨慎。

English Version

In-depth Analysis of Fuyuan Pharma 2025 Annual Dividend Implementation Announcement

1. Key Highlights

• Dividend Ratio: RMB 0.5 (tax inclusive) cash dividend per A-share.
• Differentiated Dividend: This scheme uses differentiated distribution. Actual participating shares total 468 million (12 million shares in the company’s buy-back account are excluded).
• Key Dates: Record date is June 1, 2026; ex-dividend and dividend payment date is June 2, 2026.
• Ex-dividend Reference Price: Due to differentiated dividend, the adjusted per-share dividend is RMB 0.49, so the reference price is “previous close – 0.49”.
• Cash Dividend Only: No bonus shares or capital reserve increase; only cash dividend is distributed.

2. Shareholder Impact & Price Sensitive Information

• Buy-back Shares Excluded: The 12 million buy-back shares do not participate in distribution. Remaining shareholders benefit from higher per-share dividend.
• Tax Treatment:
  • Individuals and funds: Dividend not withheld; taxed upon share transfer based on holding period (≤1 month: 20%; 1 month–1 year: 10%; >1 year: tax exempt).
  • QFII & Stock Connect investors: Company withholds 10% tax; after-tax dividend is RMB 0.45/share.
  • Institutions/legal entities: Responsible for own tax filing. Receive RMB 0.50 per share.
• Dividend Distribution Channels:
  • ChinaClear Shanghai will distribute to unrestricted shareholders; designated accounts receive automatically.
  • Main shareholders (Xinhecheng Holding, Xinchang Qinjing Investment, Beijing Huakang Taifeng, Xuancheng Renhe Fund) receive direct distribution.
• Price Sensitive Information:
  • High cash dividend reflects strong profitability and robust cash flow, likely to positively affect sentiment and share price.
  • Due to differentiated scheme, actual dividend per share is slightly lower than headline figure. Investors should consider ex-dividend price and cash received.
  • Concentration of dividends among floating shareholders increases per-share benefit.

3. Timeline & Investor Tips

Dividends will be credited automatically for accounts with designated trading; others must complete designation to receive payment.

4. Investor Focus

• The high cash dividend demonstrates the company’s commitment to shareholder returns, potentially attracting long-term investors.
• Complex tax rules: Investors are advised to review their holding periods and tax responsibilities.
• For queries, contact Board Secretary Office: +86 10-65020399.

5. Conclusion

Fuyuan Pharma’s dividend plan underlines its stable operations and healthy cash flow, likely to support the share price. Investors should pay attention to post-ex-dividend price and tax implications.

Disclaimer: This article is based on public information and does not constitute investment advice. Investments are risky—please proceed with caution.

View 福元医药 Historical chart here